The estimated Net Worth of Harold Wayne Rosenberger is at least 98.4 千$ dollars as of 30 August 2013. Harold Rosenberger owns over 3,000 units of Simulations Plus stock worth over 98,430$ and over the last 16 years Harold sold SLP stock worth over 0$.
Harold has made over 1 trades of the Simulations Plus stock since 2013, according to the Form 4 filled with the SEC. Most recently Harold exercised 3,000 units of SLP stock worth 5,400$ on 30 August 2013.
The largest trade Harold's ever made was exercising 3,000 units of Simulations Plus stock on 30 August 2013 worth over 5,400$. On average, Harold trades about 333 units every 0 days since 2008. As of 30 August 2013 Harold still owns at least 3,000 units of Simulations Plus stock.
You can see the complete history of Harold Rosenberger stock trades at the bottom of the page.
Harold's mailing address filed with the SEC is 42505, 10th Street West, Lancaster, California, 93534, United States.
Over the last 21 years, insiders at Simulations Plus have traded over 70,055,940$ worth of Simulations Plus stock and bought 24,000 units worth 1,395,840$ . The most active insiders traders include Walter Swoltosz Virginia E ...、Walter S Woltosz、Momoko A Beran. On average, Simulations Plus executives and independent directors trade stock every 37 days with the average trade being worth of 571,025$. The most recent stock trade was executed by Jill Fiedler Kelly on 9 September 2024, trading 2,250 units of SLP stock currently worth 21,848$.
simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res
Simulations Plus executives and other stock owners filed with the SEC include: